CLINUVEL PHARMACEUTICALS/ AU000000CUV3 /
2024-04-24 8:22:57 AM | Chg. +0.1150 | Volume | Bid11:57:38 AM | Ask12:00:02 PM | High | Low |
---|---|---|---|---|---|---|
9.0500EUR | +1.29% | 0 Turnover: 0.0000 |
9.0700Bid Size: 240 | 9.1650Ask Size: 240 | 9.0500 | 9.0500 |
GlobeNewswire
03-28
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
GlobeNewswire
2018-12-19
Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire
2018-06-25
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire
2017-04-12
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire
2016-06-01
Nasdaq Welcomes Additional Companies to the Nasdaq International Designation